Get the Stockscreener App
30.20
0.56%
-0.17
After Hours:
30.20
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Fierce Biotech Layoff Tracker 2025: Viracta shuts down; Layoffs hit Frontier - Fierce Biotech
Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and MaplebearJohnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - GlobeNewswire
Geographic Atrophy Market Poised for Massive Growth - openPR
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Inside Apellis' Strategic Move: New Talent Secured with 7,805 RSU Compensation Package - StockTitan
(APLS) Technical Data - news.stocktradersdaily.com
KBC Group NV Has $3.33 Million Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Cedric Francois Sells 2,824 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock - MarketBeat
Sippican Capital Advisors Sells 9,560 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Morgan Stanley's Strategic Acquisition of Apellis Pharmaceuticals Shares - GuruFocus.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Update - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan Sells 546 Shares - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells $24,354.00 in Stock - MarketBeat
Short Interest in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Decreases By 16.0% - MarketBeat
Apellis Pharmaceuticals' (APLS) Sector Perform Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel Sells $20,516.40 in Stock - MarketBeat
Apellis Pharmaceuticals chief development officer sells $8,207 in stock - MSN
Apellis Pharmaceuticals chief scientific officer sells $24,386 in stock - MSN
Apellis Pharmaceuticals officer sells shares for $10,776 - MSN
Apellis Pharmaceuticals chief development officer sells $8,207 in stock By Investing.com - Investing.com Canada
Layoff Tracker: Rentschler’s Cell and Gene Therapy Exit Could Affect Up to 30 - BioSpace
Apellis Pharmaceuticals chief scientific officer sells $24,386 in stock By Investing.com - Investing.com Australia
Apellis Pharmaceuticals general counsel sells $20,518 in stock By Investing.com - Investing.com Canada
Apellis Pharmaceuticals CFO sells $16,119 in stock - MSN
Apellis Pharmaceuticals officer sells shares for $10,776 By Investing.com - Investing.com Australia
Apellis Pharmaceuticals CFO sells $16,119 in stock By Investing.com - Investing.com Canada
Apellis Pharmaceuticals general counsel sells $20,518 in stock - Investing.com
Mizuho maintains Neutral rating on Apellis stock, price target $30 - MSN
Sector Update: Health Care -January 28, 2025 at 08:57 am EST - Marketscreener.com
Apellis Receives Approval of SYFOVRE (pegcetacoplan) in Australia for Geographic Atrophy (GA) - Marketscreener.com
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):